SHIPPEO
Unipart, a supply chain solutions and performance improvement technologies business, has chosen Shippeo, a global leader in real-time multimodal transportation visibility as its supply chain visibility partner.
Leveraging Shippeo’s unparalleled real-time data and advanced transportation visibility technology, Unipart Logistics enhances its Lead Logistics Partner (LLP) capability to enable customers to better manage suppliers across road, sea, and air logistics, as well as warehousing and in-plant logistics. This empowers them to build resilience and reduce environmental impact across their global supply chain network.
Shippeo aggregates the industry’s largest global dataset, facilitating intelligent routing decisions across various modes of transportation worldwide. Through smarter carrier routing and management, ETA calculation, and in-transit management solutions, Shippeo will provide real-time insights, empowering users of the LLP to bolster supply chain resilience and sustainability, all while prioritising customer-centric operations. LLP users will also gain live insights into inventory, costs, OTIF, and scope 3 CO2 emissions throughout the supply chain, equipping logistics leaders with actionable data to drive informed business decisions. This continuous monitoring offers early alerts for supply chain issues and enables proactive mitigation or avoidance of disruptions.
Welcoming Unipart to Shippeo strengthens our UK presence and aligns with our shared vision for efficient, customer-centric, and sustainable supply chains. Their commitment to innovation and operational excellence perfectly complements Shippeo's real-time visibility platform. We're confident that our platform will empower Unipart to enhance their LLP platform, providing real-time visibility and control to manage their customer's supply chain, boost satisfaction, and achieve their sustainability goals. This partnership underscores our dedication to UK businesses and the increasing demand for real-time transportation visibility solutions," said Stuart Morrison, Shippeo Vice President, Northern Europe.
“Two trusted brands working in partnership delivering the complete end to end supply chain solution is critical to the success of any customer's supply chain. The need for real time visibility matched with the knowledge and expertise of Uniparts LLP offering deliver’s an efficient and sustainable solution. The data that the Shippeo system provides not only benefits the LLP and its customers for operational control, management and supply chain improvements but also supports and focuses all of our efforts on the need for a sustainable future,” said Lee Fox, Sector Strategy and Business Development Director for LLP at Unipart.
You can Shippeo and Unipart at Multimodal UK from June 11-13 in Birmingham. Don't miss the session with Shippeo’s Chief Product Officer, Anand Medepalli, and Unipart’s Director of Business Development and Sector Strategies, Adam Jones, at 10:30 AM GMT on June 11th. They will discuss "Shaping Logistics' Future: Shippeo & Unipart's Real-Time Visibility Story."
About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, Jaguar Land Rover, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, Siemens Energy and XPO Logistics, trust Shippeo to track more than 32 million shipments per year across 110 countries. Learn more at www.shippeo.com, LinkedIn, Facebook, X (formerly Twitter)
About Unipart
Unipart Group is a leading provider of supply chain solutions and performance improvement technologies. It has deep expertise and breadth of capabilities in seven core sectors – automotive, rail and public transport, technology, healthcare, aerospace and defence, e-commerce, consumer and retail, and industrial sectors.
Unipart’s customer promise is: ‘To understand the real and perceived needs of our customers better than anyone else and to serve them better than anyone else.’ At the heart of delivering this is ‘The Unipart Way’, which is demonstrated in the way colleagues think, work and behave. The Unipart Way empowers more than 12,000 colleagues across operations in the UK and 20 international markets with a continuous improvement mindset, delivering operational excellence and added value for customers, everyday.
In 2023 Unipart delivered £1bn turnover. In 2024 it is celebrating the 50th Anniversary of the Unipart brand, having been a division within British Leyland in 1974 and becoming a private company through a management buyout in 1987.
Unipart is committed to setting the highest standards for colleague safety and wellbeing and sustainability. In 2023 it became the first organisation ever to be recognised with a world-class safety, wellbeing and sustainability ‘treble’ by the British Safety Council, and had its ambitious near-term and net-zero targets validated by the Science Based Targets initiative (SBTi).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603664536/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom